Self-reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis

Masoud Etemadifar^{1,2}; Amir Parsa Abhari^{2,3}; Hosein Nouri^{2,3}; Amirhosein Akhavan Sigari²; Seyed Mohammad Piran Daliyeh²; Mohammad Reza Maracy⁴; Mehri Salari⁵; Shiva Maleki²; Nahad Sedaghat^{2,3*};

1. Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2. Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
3. Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran.
4. Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
5. Department of Neurology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

*Corresponding Author:

Nahad Sedaghat

Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Email: nahad.sedaghat@gmail.com

ORCID: 0000-0002-2796-6791

Abstract

To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were interviewed. 16.2% of the vaccinated pwMS reported at least one neurological symptom in their respective at-risk periods (ARP) – a period from the first until two weeks after the second vaccine dose. In a multivariable logistic regression model, presence of comorbidities ($P = 0.01$), being on natalizumab ($P = 0.03$), and experiencing post-vaccination myalgia ($P < 0.01$) predicted the development of post-vaccination neurological symptoms. One MS relapse, one COVID-19 contraction, and one ulcerative colitis flare after the first, and four MS relapses after the second dose, were the only reported serious adverse events during the ARPs. A multivariable Poisson regression model accounting for possible confounders failed to show any statistically-significant increase in relapse rates during the ARPs of vaccinated, compared to the prior year of unvaccinated pwMS ($P = 0.78$). Hence, the BBIBP-CorV vaccine does not seem to affect short-term MS activity. Furthermore, as 83.33% of the unvaccinated pwMS reported fear of possible adverse events to be the reason of their vaccination hesitancy, provision of misinformed pwMS with evidence-based consultations in this regard is encouraged.

Key words: multiple sclerosis; SARS-CoV-2, COVID-19 vaccines; vaccine safety; adverse events; BBIBP-CorV.

Introduction

Nearly a year passed the emergence of the coronavirus disease 2019 (COVID-19), several vaccines were developed and approved. The BNT162b2 (Pfizer-Biontech), mRNA-1273 (Moderna), ChAdOx1 (AstraZeneca), and BBIBP-CorV (Sinopharm) vaccines are currently being used worldwide and all have received authorization from the world health organization (Coronavirus Disease (COVID-19)).

Vaccination is considered as the most prominent scheme to halt the rapid surge of COVID-19 and end the pandemic; However, administration of vaccines in people with multiple sclerosis (pwMS) has always been a matter of controversy. These concerns arose considering the potential effect of disease-modifying therapies (DMTs) on the immunogenicity of the vaccines or probable vaccine-associated worsening of the disease course. Theoretically, vaccines may either trigger and increase the risk of MS in healthy individuals, or increase relapses in already-diagnosed pwMS, as seen in the controversial cases of yellow fever vaccines (Farez and Correale 2011; Reyes et al. 2020). Nevertheless, no other population-level association has been identified between vaccination and MS development or relapses (Confavreux et al. 2001). Moreover, this seems to be also true for COVID-19 vaccines based on the limited data available to date (Achiron A., Dolev M., et al. 2021; Ali Sahraian et al. 2021). Based on our observations in the clinic however, pwMS are concerned about the safety of COVID-19 vaccination, considering their disease. Therefore, providing evidence-based consultations and reasoning has gained more importance among them.

Inadequate data was available at the time of initiation of this study on the safety of the BBIVP-CorV COVID-19 vaccine in pwMS. Therefore, this preliminary study aimed to assess the BBIVP-CorV vaccine's short-term safety in a relatively large cohort of pwMS in Iran.

Materials and Methods

Following the STROBE guidelines, a questionnaire, first created by a team of researchers, was used to collect information from the pwMS. These patients were identified and assessed for eligibility via an online platform (Porsline.ir), distributed in vaccination centers and MS forums across Iran from June 7th until 12th, 2021, in which they entered their information, including their telephone number. A trained nurse collected the information on eligible patients via telephone calls, from June 18th until 24th, 2021. Patients who did not provide their telephone numbers were excluded. Eligible participants were pwMS with a minimum disease duration of one year who either received the BBIVP-CorV vaccine or no vaccine. Prior sample size calculation was not performed, and therefore, no goal was set for the sample size.

In the vaccinated cohort, outcomes were obtained pertaining to an at-risk period (ARP) from the first dose until 2 weeks after the second, and in the unvaccinated cohort, pertaining to a one-year period before the study. All variables and their measurement are summed up in Table 1. An MS relapse was defined as development of new, or worsening of pre-existing neurological symptoms, lasting for at least 24 hours without concurrent fever/infection, preceded by 30 days of neurological improvement/stability. [Table 1 near hear]

Baseline characteristics of the vaccinated and unvaccinated cohorts were compared using proper (non)parametric statistical tests. Among the vaccinated pwMS, a multivariable logistic regression model was used to investigate the effect of age, sex, presence of comorbidities, MS type and duration, DMTs, and presence each general post-vaccination symptoms on development of neurological post-vaccination symptoms. The measures pertaining to the primary outcome i.e. MS relapse rate, were compared between the vaccinated and unvaccinated cohorts using a multivariable Poisson regression model accounting for age, sex, MS duration, MS type, DMT,

and offset for observation period i.e. the ARP for the vaccinated and the prior year for the unvaccinated pwMS. A two-tailed P value of 0.05 was considered as the threshold for diagnosis of statistical significance. Analyses were carried out using SPSS23 (IBM Inc.) for MacOS.

Results

Figure 1 summarizes the participant flow of the study. Table 2 summarizes the general baseline characteristics, and Table 3 the post-vaccination symptoms of the participants. The vaccinated and unvaccinated cohorts differed regarding their duration of MS ($P < 0.01$), previous COVID-19 history ($P < 0.01$) and their DMTs ($P = 0.05$). A greater portion of pwMS were on no DMTs in the unvaccinated cohort, and a greater portion were on high-efficacy DMTs in the vaccinated cohort. [Figure 1 and Table 2 near here]

84 (16.2%) of the vaccinated participants experienced at least one post-vaccination neurological symptom, among which motor symptoms and vertigo were more common (Table 3). Presence of comorbidities (B [SE]: 0.76 [0.30], $P = 0.01$), being on natalizumab therapy (B [SE]: 2.63 [1.24], $P = 0.03$), and experiencing post-vaccination myalgia (B [SE]: 0.73 [0.28], $P < 0.01$), predicted the development of post-vaccination neurological symptoms in the multivariable logistic regression model. Only five vaccinated women with MS (two secondary progressive and three relapsing-remitting) experienced neurological symptoms during the ARP that met the criteria for an MS relapse, two were on dimethyl fumarate, one on glatiramer acetate, one on fingolimod, and one on rituximab therapy. One of the relapses followed the first and four followed the second dose of the vaccine. All relapses were followed by either partial or complete improvement after treatment with corticosteroids. The multivariable Poisson regression model did not indicate any significant difference between the relapse rates of vaccinated pwMS in the

ARP and the unvaccinated pwMS in the prior year (Table 4). Furthermore, apart from one case of COVID-19 and one case of ulcerative colitis flare – both after the first dose – no other serious adverse events were reported. [Table 3 and Table 4 near hear]

Among the unvaccinated pwMS, the main reason for vaccination hesitancy was reported to be fear of possible adverse events (83.33%). Other reasons included pregnancy and lactation-related reasons (4.60%), believing that they have already obtained immunity after contracting COVID-19 (4.02%), waiting for other types of vaccines (1.72%), fears of conspiracy (2.30%), disbelieving vaccination (3.45%), and unawareness of eligibility (0.57%).

Discussion

Our results suggest that the BBIVP-CorV vaccine does not increase the risk of relapse in pwMS, although a relatively small proportion of vaccinated pwMS may experience neurological symptoms. 83.7% of our participants did not develop any neurological sequelae following vaccination, and only 6 (1.2%) experienced post-vaccination MS relapses. However, we acknowledge the probability of possibly missed relapses and the short observation period of our study, which could have accounted for the relatively low relapse frequency in our study. In a relatively similar cohort of 555 pwMS vaccinated with BNT162b2, followed up 14-21 days after the second dose of the vaccine, 13 (2.3%) acute MS relapses were reported (Achiron A., Dolev M., et al. 2021). In another study on 29 pwMS vaccinated with ChAdOx1 and four with BNT162b2, no lasting neurological adverse event or MS relapse was observed in at least two months of follow-up (Allen-Philbey et al. 2021). Similar to the present study, a more recent study on Iranian pwMS receiving the first dose of BBIBP-CorV also did not find an association between vaccination and short-term MS activity, although five post-vaccination MS relapses

were reported (Ali Sahraian et al. 2021). Whether or not the mentioned relapses could be attributed to COVID-19 vaccines is unclear.

The BBIBP-CorV is an inactivated virus, administered in a two-dose regimen (Wang et al. 2020). Its phase 1 and 2 trials and a study on a cohort of 89 non-MS individuals found no neurological adverse event or serious side effect (Abu-Hammad et al. 2021; Xia et al. 2021). In its phase 3 trial, apart from injection-site reactions, myalgia and headache were the most frequent systemic adverse events; five individuals experienced more severe systemic adverse events affecting the nervous system (Al Kaabi et al. 2021). Systemic adverse events were more frequent after the first dose than the second in our study. Nevertheless, numerous studies have shown promising results in pwMS following the administration of inactivated vaccines (e.g., influenza or tetanus toxoid vaccines) (Kaufman et al. 2014; Olberg et al. 2018; Metze et al. 2019).

The practical efficacy of neither BBIVP-CorV vaccine nor the other authorized vaccines by WHO for emergency use has been identified yet among pwMS. This issue is of crucial value given the documented hindering effect of some DMTs – namely sphingosine 1-phosphate receptor (S1PR) modulators and anti-CD20 therapies – on proper immunization against COVID-19 (Achiron Anat et al. 2021; Achiron A., Mandel M., et al. 2021; Buttari et al. 2021; Chilimuri et al. 2021; Etemadifar Masoud; et al. 2021; Etemadifar M. et al. 2021; Gallo et al. 2021; Sormani et al. 2021). Accordingly, the effect of DMTs on practical vaccination efficacy in pwMS requires further investigation.

The reasons for vaccination hesitancy among the present study's cohort of unvaccinated pwMS clarifies the role of misinformation in preventing pwMS from getting vaccinated. Providing evidence-based consultations and reasoning by their neurologists is an encouraged strategy to

encounter misinformation among the pwMS. Setting mandates is the next possible option, although it may not be required if the pwMS are provided adequate evidence-based information. In conclusion, the BBIVP-CorV COVID-19 vaccine seems relatively safe to administer in pwMS as it does not seem to evoke severe neurological symptoms or MS relapses. Like other COVID-19 vaccines, its efficacy among pwMS remains to be investigated in more controlled studies.

Limitations

Several limitations apply to this work because of its remote nature: I) considering the limited framework of the study, we could not review the participants' medical records to perform self-controlled analyses, II) the outcome measurements were performed in a self-reporting manner, which might not have been accurate, and III) the study lacked precise clinical and paraclinical evaluations.

Disclosures

Disclosure of interest

The authors report no conflict of interests.

Funding

This study received no funding.

Ethics

This study was approved by the ethics committee of Isfahan University of Medical Sciences. Considering the remote nature of the study, written consent could not be obtained from the participants, although they were completely informed about the aims of this study and all conveyed consent for anonymized publication of their information, both in the online surveys

and on the telephone calls. No deanonymized data was stored by the investigators in any way, to ensure the privacy protection of the participants.

Data Availability Statement

The anonymized data will be shared with any qualified investigator upon reasonable request.

References

- Abu-Hammad O, Alduraiddi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, Nourwali I, Qasem F, Dar-Odeh N. 2021. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. *Vaccines*. 9(6):577.
- Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U et al. 2021. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. *Mult Scler*. 27(6):864-870. eng.
- Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R. 2021. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. *Therapeutic Advances in Neurological Disorders*. 14:17562864211012835.
- Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R et al. 2021. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. *Ther Adv Neurol Disord*. 14:17562864211012835. eng.
- Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J et al. 2021. Effect of 2 Inactivated SARS-CoV-2

Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.

Jama. eng.

Ali Sahraian M, Ghadiri F, Azimi A, Naser Moghadasi A. 2021. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine. 39(43):6347-6350. eng.

Allen-Philbey K, Stennett A, Begum T, Johnson A, Dobson R, Giovannoni G, Gnanapavan S, Marta M, Smets I, Turner B. 2021. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 52:103028.

Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, Fantozzi R. 2021. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Multiple Sclerosis and Related Disorders. 52:102983.

Chilimuri S, Mantri N, Gongati S, Zahid M, Sun H. 2021. COVID-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab. Vaccines. 9(3):219.

Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. 2001. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 344(5):319-326. eng.

Coronavirus Disease (COVID-19). World Health Organization; [accessed 2021 June 30]. <https://extranet.who.int/pqweb/vaccines/covid-19-vaccines>.

Etemadifar M, Sedaghat N, Nouri H, Lotfi N, Chitsaz A, Khorvash R, Zolfaghari H, Ghasemi Movaghar AP, Mohammad; , Salari M. 2021. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV

(Sinopharm) inactivated virus vaccination: same story, different vaccine. [Preprint].
 Available at SSRN: <https://ssrncom/abstract=3942531>.
 Etemadifar M, Sigari AA, Sedaghat N, Salari M, Nouri H. 2021. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. *Hum Vaccin Immunother*.1-3. eng.
 Farez MF, Correale J. 2011. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. *Archives of neurology*. 68(10):1267-1271.
 Gallo A, Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, d'Ambrosio A, Coppola N, Galdiero M, Tedeschi G. 2021. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. *Neurological Sciences*.1-4.
 Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. 2014. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. *Journal of the neurological sciences*. 341(1-2):22-27.
 Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, Zettl UK. 2019. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. *CNS neuroscience & therapeutics*. 25(2):245-254.
 Olberg H, Eide G, Cox R, Jul-Larsen Å, Lartey S, Vedeler C, Myhr KM. 2018. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. *European journal of neurology*. 25(3):527-534.

242 Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Lambourne J,
243 Marta M, Turner B, Gnanapavan S. 2020. Protecting people with multiple sclerosis
244 through vaccination. *Practical neurology*. 20(6):435-445.

245 Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, Da Rin G,
246 Serrati C, Gandoglia I, Tassinari T. 2021. Effect of SARS-CoV-2 mRNA vaccination in
247 MS patients treated with disease modifying therapies. *EBioMedicine*.103581.

248 Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J.
249 2020. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent
250 protection against SARS-CoV-2. *Cell*. 182(3):713-721. e719.

251 Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z. 2021.
252 Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a
253 randomised, double-blind, placebo-controlled, phase 1/2 trial. *The Lancet Infectious*
254 *Diseases*. 21(1):39-51.

255

256

Fig. 1; Study flow diagram

260 *Table 1; Study variables and their measurement*

Variables	Measurement
Primary outcome	
1. Number of MS relapses	Count
Secondary outcomes	
2. General post-vac symptoms	Categorical
3. Neurological post-vac symptoms	Categorical
4. Possible serious events	Count
5. Reason for vac-hesitancy	Nominal
Other	
6. Duration since the first dose	Number of weeks
7. Age	Years
8. Sex	Female/male
9. Disease duration	Years
10. MS type	Relapsing-remitting/progressive
11. Disease-modifying therapy	Categorical
12. Number of Comorbidities	Count
13. Previous COVID-19	Binary
Abbreviations: vac, vaccination; MS, multiple sclerosis;	

261

262

263 *Table 2; General characteristics of participants*

General Characteristics	Vaccinated (n = 517)	Unvaccinated (n = 174)	P
Mean age (SD)	37.81 (8.74)	36.75 (10.20)	0.19
Sex (female/male)	397 / 120	137 / 36	0.18
Presence of comorbidities (Yes/No)	101 / 416	31 / 143	0.62
Median MS duration (Range)	8 (29)	6 (20)	<0.01
MS phenotype (R/P)	427 / 90	154 / 20	<0.01
History of COVID-19 (Yes/No)	208 / 309	28 / 146	0.07
DMTs (n, %)			0.05
• No DMT	20 (3.87)	14 (8.04)	
• Interferons	161 (31.14)	50 (28.74)	
• Glatiramer Acetate	53 (10.25)	22 (12.64)	
• Dimethyl Fumarate	100 (19.34)	41 (23.56)	
• Teriflunomide	41 (7.93)	17 (9.77)	
• Fingolimod	48 (9.28)	14 (8.05)	
• Natalizumab	4 (0.77)	1 (0.57)	
• Rituximab	90 (17.41)	15 (8.62)	
Vaccination status		NA	
• One dose	100 (19.3)		
• Two doses	417 (80.7)		
Median ARP (Range)	6 (4)		
Abbreviations: SD, standard deviation; R, relapsing; P, progressive; DMT, disease-modifying therapy; ARP, at-risk period; NA, not applicable.			

264

265

266 *Table 3; Post-vaccination symptoms of participants during the ARPs.*

Symptoms	pwMS vaccinated with BBIVP-CorV	
GENERAL SYMPTOMS	After first dose (n = 517)	After second dose (n = 417)
• No symptoms	222 (42.9%)	228 (54.7%)
• Fever	97 (18.8%)	56 (13.4%)
• Headache	122 (23.6%)	78 (18.7%)
• Myalgia	132 (25.5%)	84 (20.1%)
• Fatigue	106 (20.5%)	66 (15.8%)
• Hypersensitivity	55 (10.6%)	41 (9.8%)
• Pruritus	19 (3.7%)	12 (2.9%)
• Urticaria	3 (0.6%)	1 (0.2%)
• Gastrointestinal	7 (1.4%)	0
• Dyspnea	3 (0.6%)	0
• Dizziness	5 (1%)	0
• Other	15 (2.9%)	0
NEUROLOGICAL SYMPTOMS	After first or second dose (n = 517)	
• No symptoms	433 (83.7%)	
• Motor	32 (6.2%)	
• Sensory	12 (2.3%)	
• Diplopia	14 (2.7%)	
• Vision impairments	17 (3.3%)	
• Vertigo	23 (4.4%)	
• Other	19 (3.7%)	
Abbreviations: pwMS, people with multiple sclerosis;		

267

268

269 *Table 4; Results of multivariable Poisson regression.*

Predictors	Multivariable Poisson regression (n = 691, outcome: MS relapse)		
	B	SE	P
Age (per year)	-0.037	0.026	0.157
Sex			
- Male	(ref)		
- Female	-0.094	0.576	0.871
History of COVID-19			
- No	(ref)		
- Yes	0.404	0.564	0.473
MS type			
- Relapsing	(ref)		
- Progressive	0.160	0.723	0.824
MS duration (per year)	0.054	0.050	0.283
DMT			
- No DMT	(ref)		
- Injectables (IFN, GA)	-0.251	1.200	0.834
- Orals (DMF, TFN, FNG)	0.565	1.116	0.612
- Infused (RTX, NTZ)	0.541	1.214	0.656
Cohort			
- Unvaccinated	(ref)		
- Vaccinated	0.163	0.579	0.779
Abbreviations: MS, multiple sclerosis; ref, reference; DMT, disease-modifying therapy; IFN, interferons; GA, glatiramer acetate; DMF, dimethyl fumarate; TFN, teriflunomide; FNG, fingolimod; RTX, rituximab; NTZ, natalizumab.			

270